Viral Vector Manufacturing Market Report 2026

The viral vector manufacturing market size has grown rapidly in recent years. It will grow from $8.26 billion in 2025 to $9.9 billion in 2026 at a compound annual growth rate (CAGR) of 19.9%. The growth in the historic period can be attributed to limited manufacturing capacity, high production cost, reliance on traditional gene delivery methods, regulatory barriers, fragmented supply chains.

The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $21.31 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. The growth in the forecast period can be attributed to growing demand for gene and cell therapies, advancements in viral vector technology, increased R&D investments, expansion of contract manufacturing organizations, rising adoption of personalized medicine. Major trends in the forecast period include gene therapy innovation, viral vector safety optimization, scalable manufacturing processes, regulatory compliance enhancement, advanced upstream and downstream processing.

The rising prevalence of cancer and infectious diseases is expected to drive the growth of the viral vector manufacturing market in the coming years. Infectious diseases are conditions caused by viruses or their toxic byproducts, transmitted to susceptible hosts through contact with infected people, animals, or objects. Cancer comprises a wide range of illnesses in which abnormal cells grow uncontrollably, invade neighboring tissues, and spread to other organs. Viral vectors are used to produce tumor antigens that trigger the body’s anticancer immune response and have served as vaccine platforms in preclinical and clinical trials for various infectious diseases. For instance, in July 2024, the Australian Institute of Health and Welfare reported that cancer diagnoses in Australia rose from 160,570 in 2022 to 164,694 in 2023, reflecting a significant yearly increase. Additionally, in August 2024, the UK Health Security Agency reported 368 measles cases in England in 2023, a nearly sevenfold rise from 53 cases in 2022, highlighting the growing prevalence of infectious diseases. Consequently, the increasing incidence of cancer and infectious diseases is fueling the viral vector manufacturing market.

Key companies in the viral vector manufacturing market are focusing on advanced platforms tailored for efficient viral vector production. Viral vector platforms are integrated systems designed to optimize the development and processing of vectors for applications such as gene therapy and vaccine production. For example, in May 2023, AGC Biologics, a US-based global biopharmaceutical CDMO, launched the BravoAAV and ProntoLVV platforms to provide flexible and accelerated vector development for cell and gene therapy programs. These platforms enable GMP-compliant product delivery within nine months, supported by a global regulatory and supply network and in-house plasmid DNA services. With customizable processes, templated material strategies, and prequalified analytical methods, these platforms significantly contribute to the projected $5.5 billion viral vector manufacturing market by 2035 by meeting rising demand for efficient gene therapy and vaccine production.

In January 2024, Oxford Biomedica Plc, a UK-based biotechnology company, acquired ABL Europe from Institut Mérieux for $16 million (15 million euros). This acquisition provides Oxford Biomedica with manufacturing facilities in Lyon and Strasbourg, France, expanding its multi-viral vector CDMO capabilities across six sites in the EU, U.S., and U.K. ABL Europe is a France-based CDMO specializing in viral vector manufacturing services.

Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

North America was the largest region in the viral vector manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the viral vector manufacturing market by increasing costs for importing raw materials, bioreactors, and specialized lab equipment, creating challenges for manufacturers in meeting production demands. The most affected segments include upstream and downstream processing equipment, particularly in regions like North America and Europe that rely on imports from Asia-Pacific hubs. Despite these challenges, tariffs have encouraged local manufacturing and investment in domestic production facilities, which could strengthen supply chain resilience and reduce long-term dependency on foreign suppliers.

The viral vector manufacturing market research report is one of a series of new reports that provides viral vector manufacturing market statistics, including viral vector manufacturing industry global market size, regional shares, competitors with a viral vector manufacturing market share, detailed viral vector manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector manufacturing industry. This viral vector manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector manufacturing involves producing viral vectors, which are tools used to deliver genetic material into cells. Viral vectors enable gene transfer, allowing specific cell types or tissues to express therapeutic genes.

The main types of viral vector manufacturing include adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. Adenoviral vectors are double-stranded DNA vectors that are non-enveloped. These vectors are applied in the treatment of cancer, genetic disorders, infectious diseases, and more, using workflows such as upstream and downstream processing. Their applications include gene and cell therapy development, vaccine development, biopharmaceutical and pharmaceutical research, and biomedical studies, and they are utilized by research organizations, biotechnology and pharmaceutical companies, and other institutions.

The viral vector manufacturing market includes revenues earned by entities through the production, packaging, and labeling of viral vector vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.